These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36739366)

  • 41. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
    Mohamed YI; Duda DG; Awiwi MO; Lee SS; Altameemi L; Xiao L; Morris JS; Wolff RA; Elsayes KM; Hatia RI; Qayyum A; Chamseddine SM; Rashid A; Yao JC; Mahvash A; Hassan MM; Amin HM; Kaseb AO
    Oncotarget; 2022 Dec; 13():1314-1321. PubMed ID: 36473155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downstaging with atezolizumab-bevacizumab: a case series.
    Kulkarni AV; Kumaraswamy P; Menon B; Sekaran A; Rambhatla A; Iyengar S; Alla M; Venishetty S; Ramachandra SK; Premkumar GV; Sharma M; Rao PN; Reddy DN; Singal AG
    J Liver Cancer; 2024 Sep; 24(2):224-233. PubMed ID: 38797993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
    Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A Case of Multiple Postoperative Recurrence of Hepatocellular Carcinoma Successfully Treated with Atezolizumab plus Bevacizumab].
    Fujii J; Shinke G; Takeda Y; Ohmura Y; Katsura Y; Kinoshita M; Aoyama S; Kihara Y; Katsuyama S; Ikeshima R; Hiraki M; Sugimura K; Masuzawa T; Hata T; Murata K
    Gan To Kagaku Ryoho; 2023 Jan; 50(1):96-98. PubMed ID: 36759998
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.
    Nosaka T; Murata Y; Akazawa Y; Tanaka T; Takahashi K; Naito T; Matsuda H; Ohtani M; Imamura Y; Nakamoto Y
    Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
    Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
    Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
    Singal AG; Özgürdal K; Fan X; Vassilev Z; Pan X; Multani JK; Chen CC; Zhou Z; He J; Pisa F
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067235
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A case of immune checkpoint inhibitor-associated hemophagocytosis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.
    Hidaka H; Kamata H; Uojima H; Iwasaki S; Iida J; Nakazawa T; Kusano C
    Clin J Gastroenterol; 2024 Oct; ():. PubMed ID: 39361211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Kuroyanagi K; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    Cancer Med; 2024 Jan; 13(1):e6876. PubMed ID: 38133557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A successful case of transarterial chemoembolization for hyperprogressive disease induced by immunotherapy in a patient with unresectable hepatocellular carcinoma.
    Baterdene O; Miura K; Ueno W; Watanabe S; Tsukui M; Nomoto H; Goka R; Maeda H; Yamamoto H; Morimoto N
    Clin J Gastroenterol; 2022 Dec; 15(6):1101-1107. PubMed ID: 36088514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.
    Yu Q; Wang Y; Ungchusri E; Patel M; Kumari D; Van Ha T; Pillai A; Liao CY; Ahmed O
    J Interv Med; 2023 Nov; 6(4):187-193. PubMed ID: 38312131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma.
    Kim C; Yang H; Kim I; Kang B; Kim H; Kim H; Lee WS; Jung S; Lim HY; Cheon J; Chon HJ
    JAMA Oncol; 2022 Dec; 8(12):1825-1829. PubMed ID: 36264560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.
    Britten CD; Gomes AS; Wainberg ZA; Elashoff D; Amado R; Xin Y; Busuttil RW; Slamon DJ; Finn RS
    BMC Cancer; 2012 Jan; 12():16. PubMed ID: 22244160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
    Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Asahiro M; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Masaki T; Takayama T
    Cancer Med; 2023 Feb; 12(3):2646-2657. PubMed ID: 35964253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.
    Wang K; Xiang YJ; Yu HM; Cheng YQ; Liu ZH; Zhong JY; Feng S; Ni QZ; Zhu HF; Pan WW; Li JJ; Liang C; Zhou HK; Meng Y; Lau WY; Cheng SQ
    Front Immunol; 2023; 14():1107542. PubMed ID: 36875125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Nishikawa H; Tsuji K; Ishikawa T; Tajiri K; Koshiyama Y; Toyoda H; Ogawa C; Hatanaka T; Kakizaki S; Kawata K; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Nishimura T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Enomoto H; Kaibori M; Hiasa Y; Kudo M; ;
    Aliment Pharmacol Ther; 2024 Jul; 60(2):233-245. PubMed ID: 38716823
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
    Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
    Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
    Shen YC; Liu TH; Nicholas A; Soyama A; Yuan CT; Chen TC; Eguchi S; Yoshizumi T; Itoh S; Nakamura N; Kosaka H; Kaibori M; Ishii T; Hatano E; Ogawa C; Naganuma A; Kakizaki S; Cheng CH; Lin PT; Su YY; Chuang CH; Lu LC; Wu CJ; Wang HW; Rau KM; Hsu CH; Lin SM; Huang YH; Hernandez S; Finn RS; Kudo M; Cheng AL
    J Clin Oncol; 2024 Aug; ():JCO2400645. PubMed ID: 39197119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol.
    Ben Khaled N; Seidensticker M; Ricke J; Mayerle J; Oehrle B; Rössler D; Teupser D; Ehmer U; Bitzer M; Waldschmidt D; Fuchs M; Reuken PA; Lange CM; Wege H; Kandulski A; Dechêne A; Venerito M; Berres ML; Luedde T; Kubisch I; Reiter FP; De Toni EN
    Future Oncol; 2022 Apr; 18(12):1423-1435. PubMed ID: 35081747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.